A Phase 2 interventional study of LYT-100 and Placebo in Covid19 and Post-acute COVID-19 Respiratory Disease, sponsored by PureTech. Terminated at 31 sites in 8 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by PureTech · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 503rd largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 831st registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 818 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 185 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
PureTech is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
PureTech has 1 study filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being conducted in two parts, A and B. Part A is a randomized, double-blind, parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory complications. Part B is an Open Label Extension (OLE) study for patients who complete Part A.
Part A of this study is a randomized, double-blind, parallel arm study being conducted at approximately 35 centers globally to evaluate the safety and efficacy of LYT-100 compared to placebo in 168 adults with post-acute COVID-19 respiratory complications who were treated with mechanical ventilation, extracorporeal membrane oxygenation, non-invasive ventilation (eg CPAP or BiPAP), high-flow nasal oxygen therapy or any other means of oxygen administration in the hospital for at least 1 day and have required only low flow nasal oxygen or no oxygen supplementation for at least 72 hours prior to screening. LYT-100 or placebo will be taken daily for up to 91 days with the primary outcome of change in distance walked on the six-minute walk test performed in line with the American Thoracic Society Respiratory Society Guidelines assessed at Day 91. Secondary endpoints, including pharmacokinetics, inflammatory biomarkers, imaging, and patient-reported outcomes of dyspnea and the 36-Item Short Form Health Survey will also be evaluated.
The second part of the study, Part B, is an open-label extension in which eligible patients who completed Part A will be enrolled and treated with open-label LYT-100 for an additional 91 days. The primary endpoint for Part B of the study is to assess the longer-term safety, tolerability, and efficacy of LYT-100 through up to 182 days of treatment.
Key Inclusion Criteria:
Key Exclusion Criteria:
LYT-100 taken orally twice a day (BID) for 91 days
Drug: LYT-100
Placebo matching LYT-100 taken orally BID for 91 days
Other: Placebo
Open Label Extension: LYT-100 taken orally BID for 91 days The Open Label Extension (Part B) was terminated after results of the Double Blind Portion.
Drug: LYT-100
oral administration
Also known as: Deupirfenidone
oral administration
Change From Baseline in Distance Walked During the Six-Minute Walk Test (6MWT)
The 6MWT is a validated endpoint commonly used in clinical trial research. The 6MWT measures the distance a subject can quickly walk on a flat, hard surface in a period of 6 minutes. It evaluates the global and integrated response of all the systems involved during exercise.
Time frame: Baseline to Day 91
| Milestone | Placebo | LYT-100 |
|---|---|---|
| Started | 90 | 95 |
| Completed | 77 | 73 |
| Not completed | 13 | 22 |
| Withdrew: Adverse event | 4 | 11 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Study terminated by sponsor | 1 | 3 |
| Withdrew: Withdrawal by subject | 6 | 3 |
| Withdrew: Other-reason not available | 1 | 3 |
| Milestone | Placebo | LYT-100 |
|---|---|---|
| Started | 60 | 47 |
| Completed | 41 | 29 |
| Not completed | 19 | 18 |
| Withdrew: Adverse event | 5 | 6 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Study terminated by sponsor | 10 | 9 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Other - reason not available | 4 | 0 |
The 6MWT is a validated endpoint commonly used in clinical trial research. The 6MWT measures the distance a subject can quickly walk on a flat, hard surface in a period of 6 minutes. It evaluates the global and integrated response of all the systems involved during exercise.
| meters | Placebo | LYT-100 |
|---|---|---|
| Change From Baseline in Distance Walked During the Six-Minute Walk Test (6MWT) | 48.77 ± 9.997 | 44.28 ± 9.948 |
Collected over Data for the Double-blind Part of the study was reported for Days 1 to 91. Data for the Open-label Part of the study was reported for Days 92 to 182.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/90 (1.1%) | 3/90 (3.3%) | 19/90 (21.1%) |
| LYT-100 | 0/95 (0%) | 3/95 (3.2%) | 52/95 (54.7%) |
| Open Label Extension LYT-100 | 0/107 (0%) | 4/107 (3.7%) | 41/107 (38.3%) |
| Event | Placebo | LYT-100 | Open Label Extension LYT-100 |
|---|---|---|---|
| COVID-19Infections and infestations | 1/90 | 0/95 | 0/107 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/90 | 0/95 | 0/107 |
| Abdominal painGastrointestinal disorders | 1/90 | 0/95 | 0/107 |
| PneumoniaInfections and infestations | 0/90 | 1/95 | 0/107 |
| AppendicitisInfections and infestations | 0/90 | 1/95 | 0/107 |
| Mixed dementiaNervous system disorders | 0/90 | 1/95 | 0/107 |
| Hypertension/Vascular disorders | 0/90 | 0/95 | 1/107 |
| Drug eruptionSkin and subcutaneous tissue disorders | 0/90 | 0/95 | 1/107 |
| LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/90 | 0/95 | 1/107 |
| Hepatitis viralInfections and infestations | 0/90 | 0/95 | 1/107 |
| Event | Placebo | LYT-100 | Open Label Extension LYT-100 |
|---|---|---|---|
| NauseaGastrointestinal disorders | 1/90 | 9/95 | 3/107 |
| DyspepsiaGastrointestinal disorders | 1/90 | 6/95 | 5/107 |
| HyperglycaemiaMetabolism and nutrition disorders | 5/90 | 3/95 | 4/107 |
| Abdominal Pain UpperGastrointestinal disorders | 2/90 | 5/95 | 1/107 |
| NasopharyngitisInfections and infestations | 1/90 | 5/95 | 3/107 |
| Fibrin D Dimer IncreasedInvestigations | 1/90 | 5/95 | 2/107 |
| HeadacheNervous system disorders | 2/90 | 5/95 | 3/107 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/90 | 5/95 | 4/107 |
| RashSkin and subcutaneous tissue disorders | 1/90 | 4/95 | 4/107 |
| COVID-19Infections and infestations | 2/90 | 2/95 | 4/107 |
Information presented is based on the Intent to Treat (ITT) population which differs from the Safety Population presented in the participant flow. Please see Statistical Analysis Plan (SAP)
| Age, Continuous(years) | Placebo | LYT-100 | Total |
|---|---|---|---|
| Mean | 52.7 ± 12.49 | 56.6 ± 12.14 | 54.7 ± 12.43 |
| Age, Customized(Participants) | Placebo | LYT-100 | Total |
|---|---|---|---|
| <65 years | 67 | 69 | 136 |
| >=65 years | 18 | 23 | 41 |
| Sex: Female, Male(Participants) | Placebo | LYT-100 | Total |
|---|---|---|---|
| Female | 35 | 32 | 67 |
| Male | 50 | 60 | 110 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | LYT-100 | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 10 | 18 |
| Not Hispanic or Latino | 76 | 82 | 158 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Placebo | LYT-100 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 20 | 10 | 30 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 |
| White | 61 | 79 | 140 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 2 | 4 |
| Region of Enrollment(participants) | Placebo | LYT-100 | Total |
|---|---|---|---|
| Argentina | 5 | 8 | 13 |
| Romania | 23 | 25 | 48 |
| United States | 11 | 17 | 28 |
| Philippines | 17 | 8 | 25 |
| Ukraine | 14 | 20 | 34 |
| Brazil | 0 | 2 | 2 |
| United Kingdom | 3 | 2 | 5 |
| Moldova | 12 | 10 | 22 |
| Weight(kg) | Placebo | LYT-100 | Total |
|---|---|---|---|
| Mean | 85.45 ± 17.8 | 87.82 ± 16.99 | 86.68 ± 17.375 |
| Height(cm) | Placebo | LYT-100 | Total |
|---|---|---|---|
| Mean | 169.24 ± 10.178 | 170.68 ± 9.858 | 169.99 ± 10.01 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2020 to primary completion in Jun 2022, 18 months.
Results were first posted in Jun 2026, 3 years 11 months after primary completion. A results delay was requested in Jun 2023.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirfenidone
PureTech